SCHEMBL280375

SCHEMBL280375

Cc1ccsc1C(=O)CNc1ccncn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.47
RAB9A P51151 7/20 0.44
NPC1 O15118 6/20 0.44
PPARG P37231 1/20 0.44
NCOR2 Q9Y618 1/20 0.44
PKM P14618 2/20 0.41
NAMPT P43490 1/20 0.40
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 1/20 0.38
KDM6B O15054 1/20 0.38
KDM4A O75164 1/20 0.38
KDM5C P41229 1/20 0.38
KDM4D Q6B0I6 1/20 0.38
KDM4C Q9H3R0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL280148 0.75 ADORA2A (0.43) RAB9ANPC1NAMPTCYP1A2CYP3A4
SCHEMBL2401814 0.72 P2RX7 (0.44) RAB9APKMCYP1A2CYP3A4CYP2D6
SCHEMBL4419704 0.71 SMN1; SMN2 (0.48) PPARGCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL279924 0.71 NAMPT (0.40) GSK3BNAMPTCYP1A2CYP3A4CYP2D6
SCHEMBL4466178 0.70 P2RX7 (0.47) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL6259328 0.69 SMN1; SMN2 (0.40) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL15979696 0.68 GSK3B (0.71) GSK3BRAB9ANPC1PPARGNCOR2
SCHEMBL6133280 0.67 GSK3B (0.65) GSK3BRAB9ANPC1PPARGNCOR2
SCHEMBL5903882 0.67 GSK3B (0.65) GSK3BRAB9ANPC1PPARGNCOR2
SCHEMBL6129997 0.66 GSK3B (0.69) GSK3BRAB9ANPC1PPARGNCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL GSK3B 2918/4885RAB9A 2458/4885NPC1 3107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.